MedPath

Mobile Health Delivered Lifestyle Intervention Program in Patients With NASH

Not Applicable
Completed
Conditions
Non-alcoholic Steatohepatitis
Interventions
Behavioral: Noom Healthy Weight
Registration Number
NCT04872777
Lead Sponsor
Milton S. Hershey Medical Center
Brief Summary

There is a clear unmet clinical need for effective lifestyle intervention in patients with nonalcoholic steatohepatitis (NASH). Patients have self-identified multiple barriers to effective lifestyle intervention can be removed with a mobile health (mHealth) platform.

This study will be a proof of concept study to evaluate weight loss efficacy of Noom Healthy Weight (HW), a mHealth lifestyle intervention, in patients with NASH.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Adults age >18 years
  • NASH defined as:
  • Liver biopsy with evidence of steatohepatitis (NAS >=4) or;
  • Imaging study (e.g., ultrasound, CT, MRI) with hepatic steatosis and one of the following:
  • Fibroscan kPa >8.2 or;
  • FAST > 0.35 or;
  • FIB-4 >= 1.45 or;
  • Possession of a smartphone
Exclusion Criteria
  • Active or recent (<90 days) participation in lifestyle intervention program, including weight-loss program
  • Active weight-loss supplement use
  • Cirrhosis
  • Inability to provide informed consent
  • Institutionalized/prisoner
  • Other chronic liver disease (e.g., viral hepatitis)
  • Recent Noom use (<180 days)
  • Secondary cause of hepatic steatosis, including significant alcohol consumption (men >30g/d, women >20g/d)
  • Severe medical comorbidities/psychiatric illness at the discretion of the study PI

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Noom Healthy WeightNoom Healthy WeightFollowing study group assignment, the following procedures will be completed for the Noom HW mHealth lifestyle intervention: 1. Noom application set-up and troubleshooting on smartphone (license provided) 2. Digital scale provision (subjects may keep the scale) 3. Capture of available clinical information over preceding 28-days.
Primary Outcome Measures
NameTimeMethod
Weight16 weeks

Change in self-measured body weight

Secondary Outcome Measures
NameTimeMethod
hemoglobin A1c16 weeks

Change hemoglobin A1c (%)

histology16 weeks

Change in transient elastography or liver histology

liver enzymes16 weeks

Change in liver enzymes units per liter (alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP))

NAFLD Fibrosis Score16 weeks

change in NAFLD Fibrosis Score

Noom healthy weight engagement16 weeks

Feasibility will be assessed according to user engagement. Engaged users are defined as those who complete at least one meaningful in-application action per week (e.g., weight log, food log, exercise log, article read).

Glucose16 weeks

Change in blood glucose mg/dL

Cholesterol level16 weeks

Change in cholesterol mg/dL

Ferritin16 weeks

Change in Ferritin ng/mL

IgA level16 weeks

Change in IgA level mg/dL

Trial Locations

Locations (1)

Penn State Hershey Medical Center

🇺🇸

Marietta, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath